Brought to you by 
Guidant to license Biosensors' drug-eluting stents
Jan 2003
Executive Summary
Guidant has received an exclusive worldwide license to Biosensors International's bioabsorbable polymer formulation technology relating to everolimus-eluting stents, plus a nonexclusive license to its drug and bioabsorbable polymer formulation technology for use with other drugs.
Deal Industry
- Biotechnology
-
Medical Devices
- Biomaterials
- Implantable Devices
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Guidant to license Biosensors' drug-eluting stents
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice